

Medicines switching

Jeff Buggle

Director of Finance


NHS England – South West




The South West approach

- Following engagement with clinical pharmacist, procurement and CFO networks
- Autumn 2022 introduced 'incentive' scheme to encourage higher drug switching
- Financial incentive based on difference between Trust/ICB switch-rate and next best region ... incentive payment ONLY for stretch targets!

Dimethyl Fumarate (DMF) – Regional variation



Ustekinumab biosimilar – Gastro drug, £250m annual expenditure





Where we are now

- Still massive opportunities both in SW and nationally
- Feedback in SW suggests:
 - Enhanced CFO engagement in planning, preparation and support for switching
 - Enhanced horizon-scanning maps identifying key opportunities
- Following national CFO event, interest from two other regions to adopt similar approaches